Avidity Biosciences

    Approach: Antibody Oligonucleotide Conjugate

    Status: Phase 1/2 Clinical Trial

    Description of DM1 program on company website

    June 17, 2019 Patent Application

    Feb. 26, 2021 Patent Application

    September 14, 2019 Presentation at Myotonic conference (starts at 15:20)

    November 13, 2019 Article on Avidity's $100 million capital raise

    May 22, 2020 S-1 for IPO. States it plans to start a clinical trial of its myotonic dystrophy T1 drug, AOC 10001, by the end of 2021

    Sept. 2020 Presentation at Myotonic Dystrophy Foundation annual conference (starts at 1:19)

    Jan. 14, 2021 Endpts article regarding status of programs

    Aug. 2, 2021 press release regarding IND approval for AOC 1001 clinical trial

    Aug. 2021 Presentation for Myotonic Dystrophy Foundation

    Phase 1/2 Clinical Trial posted August 2021

    Nov. 4, 2021 Press Release announcing first patient dosed in AOC 1001 Phase 1/2 trial 

    Sept. 27, 2022 Press Release announcing clinical hold of Phase 1/2 Clinical Trial

    Dec. 14, 2022 Press Release discussing initial data from AOC 1001 Phase 1/2 Trial 

​